- Home
- DVAX vs BY Comparison
DVAX vs BY Comparison
Compare DVAX & BY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BY
- Stock Information
- Founded
- DVAX 1996
- BY 1914
- Country
- DVAX United States
- BY United States
- Employees
- DVAX N/A
- BY N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BY Major Banks
- Sector
- DVAX Health Care
- BY Finance
- Exchange
- DVAX Nasdaq
- BY Nasdaq
- Market Cap
- DVAX 1.3B
- BY 1.2B
- IPO Year
- DVAX 2004
- BY 2017
- Fundamental
- Price
- DVAX $10.26
- BY $29.28
- Analyst Decision
- DVAX Buy
- BY Hold
- Analyst Count
- DVAX 4
- BY 3
- Target Price
- DVAX $26.50
- BY $33.00
- AVG Volume (30 Days)
- DVAX 1.8M
- BY 194.3K
- Earning Date
- DVAX 08-07-2025
- BY 10-23-2025
- Dividend Yield
- DVAX N/A
- BY 1.37%
- EPS Growth
- DVAX N/A
- BY N/A
- EPS
- DVAX N/A
- BY 2.68
- Revenue
- DVAX $316,268,000.00
- BY $384,591,000.00
- Revenue This Year
- DVAX $23.23
- BY $17.73
- Revenue Next Year
- DVAX $16.57
- BY $3.08
- P/E Ratio
- DVAX N/A
- BY $10.87
- Revenue Growth
- DVAX 26.66
- BY 2.48
- 52 Week Low
- DVAX $9.22
- BY $22.63
- 52 Week High
- DVAX $14.63
- BY $32.89
- Technical
- Relative Strength Index (RSI)
- DVAX 42.08
- BY 67.73
- Support Level
- DVAX $10.27
- BY $25.96
- Resistance Level
- DVAX $11.45
- BY $28.00
- Average True Range (ATR)
- DVAX 0.45
- BY 0.74
- MACD
- DVAX -0.06
- BY 0.28
- Stochastic Oscillator
- DVAX 18.18
- BY 95.60
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.